ArticleFrontiers in immunology2025

A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving durvalumab in combination with tremelimumab.

Yang Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.